Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06520826 · ClinicalTrials.gov registry record · Phase 3
Vafseo Outcomes In-Center Experience
A Phase 3 study of Anemia of Chronic Kidney Disease, sponsored by USRC Kidney Research.
- Active
- Registry status
- Phase 3
- Development phase
- 2,200
- Enrollment target
- 5
- Study locations
NCT06520826 is a Phase 3 study of Anemia of Chronic Kidney Disease that is active but no longer recruiting, run by USRC Kidney Research. The registered enrollment target is 2,200 participants, above the 112-participant average among 4 other Anemia of Chronic Kidney Disease trials with a reported enrollment target (1864% higher). The trial reports 5 study locations across 4 states.
The verdict
NCT06520826, a Phase 3 study of Anemia of Chronic Kidney Disease, is active but no longer recruiting, sponsored by USRC Kidney Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,200 participants
- Enrollment target
- 5
- Study locations
Study Summary
This trial is an investigator-initiated, multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the safety of vadadustat administered three times per week for the treatment of anemia in in-center hemodialysis patients with End Stage Kidney Disease (ESKD). This study will obtain long-term safety data in a large sample of subjects receiving in-center hemodialysis to support adoption of three times per week vadadustat dosing.
Conditions Studied
Interventions
- DRUG Vadadustat
- DRUG Erythropoiesis Stimulating Agent
Study Locations (5)
Texas
- Dallas Renal Group - Dallas
- US Renal Care - Live Oak - Live Oak
Colorado
- USRC Kidney Research - Lone Tree
Georgia
- Nephrology and Hypertension Specialists, PC - Dalton
New Mexico
- US Renal Care - Gallup - Gallup
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,200 participants |
| Start Date | 2024-11-20 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06520826
The ClinicalTrials.gov registry entry for NCT06520826 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 2,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 112-participant average among 4 other Anemia of Chronic Kidney Disease trials with a reported enrollment target (1864% higher). The listed sponsor is USRC Kidney Research, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anemia of Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Vadadustat is the first listed.
NCT06520826 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT06520826 about?
NCT06520826 is a clinical study titled "Vafseo Outcomes In-Center Experience". This trial is an investigator-initiated, multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the safety of vadadustat administered three times per week for the treatment of anemia in in-center hemodialysis patients with End Stage Kidney Disease (ESKD). This study will o...
What is the current status of trial NCT06520826?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,200 participants. The study started on 2024-11-20. Estimated completion is 2026-06-30.
What conditions does trial NCT06520826 study?
This clinical trial studies the following conditions: Anemia of Chronic Kidney Disease.
What interventions are being tested in trial NCT06520826?
The interventions under investigation include: Vadadustat (DRUG), Erythropoiesis Stimulating Agent (DRUG).
Who is sponsoring clinical trial NCT06520826?
This trial is sponsored by USRC Kidney Research, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06520826 being conducted?
This trial has 5 study locations across Colorado, Georgia, New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia of Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
ACTIVE NOT RECRUITING · Phase 3
-
Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia
ACTIVE NOT RECRUITING · Phase 1
-
Iron Dosing Pilot Study Using Model Predictive Control
COMPLETED · Phase 4
-
Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.